Sousa, Cristovão M.
Biancur, Douglas E.
Wang, Xiaoxu
Halbrook, Christopher J.
Sherman, Mara H.
Zhang, Li
Kremer, Daniel
Hwang, Rosa F.
Witkiewicz, Agnes K.
Ying, Haoqiang
Asara, John M.
Evans, Ronald M.
Cantley, Lewis C.
Lyssiotis, Costas A.
Kimmelman, Alec C.
Article History
Received: 9 October 2015
Accepted: 7 July 2016
First Online: 10 August 2016
Change Date: 5 October 2016
Change Type: Erratum
Change Details: An Erratum to this paper has been published:
Change Details: https://doi.org/10.1038/nature19851
Competing interests
: L.C.C. owns equity in, receives compensation from, and serves on the Board of Directors and Scientific Advisory Board of Agios Pharmaceuticals. Agios Pharmaceuticals is identifying metabolic pathways of cancer cells and developing drugs to inhibit such enzymes to disrupt tumour cell growth and survival. The remaining authors have no competing financial interests to declare.